瑞卢戈利 T3630

Product Introduction
Bioactivity


英文名: Relugolix

描述: Relugolix (RVT-601) 是口服有活性的非肽性促性腺激素释放激素的拮抗剂。同 TAK-013 相比，它对人和猴子的受体具有高亲和力和强拮抗活性，它们的 IC50值分别为0.33 nM 和0.32 nM。它可用于研究性激素依赖性疾病，如子宫肌瘤、子宫内膜异位症、前列腺癌等。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 55 mg/mL(88.2 mM)


关键字: inhibit | Gonadotropin releasing hormone receptor | endometriosis | TAK 385 | GnRH Receptor | GnRH | prostate cancer | TAK385 | GNRHR | antagonistic | Inhibitor | RVT601 | uterine fibroid | FSH | Relugolix | RVT 601

相关产品: LGnRH-III, lamprey acetate(147859-97-0 free base) | Histrelin acetate | Buserelin Acetate (57982-77-1 free base) | GnRH-R antagonist 1 | Abarelix | Triptorelin acetate(57773-63-4 free base) | (R)-Elagolix | LHRH | Goserelin acetate | Linzagolix

相关库: Drug Repurposing Compound Library | Approved Drug Library | Anti-Cancer Drug Library | Membrane Protein-targeted Compound Library | Inhibitor Library | GPCR Compound Library | Anti-Cancer Clinical Compound Library | Anti-Cancer Approved Drug Library | Anti-Cancer Active Compound Library | EMA Approved Drug Library

瑞卢戈利 T3630信息由TargetMol中国为您提供，如您想了解更多关于瑞卢戈利 T3630报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途